Biogen | BIIB - Przychody Ze Sprzedaży





Obroty Zmiana Data
AbbVie USD 16.62B 840M 2025-12
Acadia Pharmaceuticals USD 284M 5.4M 2025-12
ALKERMES USD 384.5M 9.7M 2025-12
Amgen USD 9.9B 340M 2025-12
Bayer EUR 11.44B 1.78B 2025-12
Biogen USD 2.28B 250M 2025-12
BioMarin Pharmaceutical USD 875M 99M 2025-12
Bristol-Myers Squibb USD 12.5B 300M 2025-12
Eli Lilly USD 19.3B 1.7B 2025-12
Esperion Therapeutics USD 168.45M 81.14M 2025-12
Gilead Sciences USD 7.93B 130M 2025-12
Incyte USD 1.27B 240M 2026-03
Merck USD 16.4B 880M 2025-12
Moderna USD 678M 342M 2025-12
Neurocrine Biosciences USD 805.5M 10.6M 2025-12
Novartis USD 13.11B 226M 2026-03
Pfizer USD 17.58B 880M 2025-12
PTC Therapeutics USD 164.7M 46.3M 2025-12
Puma Biotechnology USD 80.54M 33.46M 2024-09
Regeneron Pharmaceuticals USD 3.88B 130M 2025-12
Sangamo BioSciences USD 356K 125K 2024-06
Sanofi EUR 11.24B 60M 2026-03
Sanofi EUR 12.14B 65M 2026-03
Sarepta Therapeutics USD 442.9M 43.5M 2025-12
Teva Pharmaceutical Industries USD 14.63B 10M 2025-12
Ultragenyx Pharmaceutical USD 207M 47M 2025-12
United Therapeutics USD 790.2M 9.3M 2025-12
Vertex Pharmaceuticals USD 3.19B 110M 2025-12